• Pharmaceutical industry success: Driven by the 1970 Patents Act and the 1984 US Hatch-Waxman Act, India's pharma sector expanded to supply 60% of the world's medicines and host over 40% of global US FDA-approved plants.
• Labor force transition: With 45% of India's workforce still in agriculture and only 11% in manufacturing, the country must execute structural shifts from farm to formal industrial employment rather than abandoning manufacturing for services.
• Regulatory cholesterol reduction: Entrepreneurship remains heavily constrained by non-statutory administrative instruments and criminal provisions that disproportionately burden small enterprises, necessitating aggressive deregulation, decriminalization, and decentralization.
• Human capital development: Upgrading the K-12 public school system and deregulating higher education are vital structural prerequisites for moving Indian software and pharmaceutical companies from low-cost volume to high-value innovation.